Visa Limits Pose Threat to Medical Science

Boston/London: From tiny start-ups to global giants, the companies that sustain the $324 billion US biotech industry are increasingly alarmed as President Donald Trump considers following his controversial travel ban with restrictions on skilled foreign immigrants.

To crank out discoveries, US biotech firms such as Amgen Inc. and Gilead Sciences Inc., as well as overseas companies with stateside operations, rely on the world’s best scientists and lower-level researchers with scarce expertise.